How the PTSD Treatment Guideline Ranks the Therapies

The 2023 U.S. Department of Veterans Affairs and Department of Defense clinical practice guideline for posttraumatic stress disorder ranks treatments with GRADE, a method that separates how confident reviewers are in the evidence from how strongly they endorse a treatment. Its headline shift was to grade each trauma-focused psychotherapy on its own record rather than folding them into one "class." When that happened, only three therapies held a strong recommendation, several respected treatments dropped to a weaker "suggest," and several medications were placed alongside them or recommended against. The guideline and its synopsis in Annals of Internal Medicine are candid that a strong endorsement demands a body of high-certainty trials, not a single encouraging study.

How GRADE ranks a treatment

GRADE (Grading of Recommendations Assessment, Development and Evaluation) asks two separate questions. First, how certain are we that the estimated effect is close to the truth? Certainty starts high for randomized trials and is downgraded for problems like risk of bias, inconsistent results across studies, indirect comparisons, imprecise estimates, and signs of publication bias. Second, given that certainty plus the balance of benefits and harms, patient values, and feasibility, how strong should the recommendation be? The panel sorts its conclusions into five tiers: strong for, weak (or "suggest") for, neither for nor against, weak against, and strong against, as the Annals synopsis (M23-2757) describes.

The distinction matters because a treatment can work and still earn only a weak recommendation if the evidence behind it is thin. A "suggest" is not a warning. It signals that reviewers expect benefit while holding real uncertainty about the size or reliability of that benefit.

Grading therapies one at a time

The most consequential change from the 2017 edition was procedural. Earlier guidelines evaluated trauma-focused psychotherapies partly as a group, so an individual therapy could inherit the strength of the category. The 2023 panel reviewed each therapy on its own evidence, the same way medications are judged, and applied GRADE more strictly. Combined with new trials, that tighter accounting reshaped the rankings.

Of the seven trauma-focused psychotherapies that carried a strong recommendation in 2017, only three kept it: prolonged exposure, cognitive processing therapy, and eye movement desensitization and reprocessing. These three rest on the deepest randomized-trial base and the most consistent effects, which is why the National Center for PTSD continues to describe them as the most strongly supported options.

Why several therapies dropped

Treatments such as brief eclectic psychotherapy, narrative exposure therapy, a specific cognitive therapy for PTSD, and written exposure therapy moved down to "suggest" or to "neither for nor against." This was not a finding that they fail. In most cases the evidence base was smaller, rested on fewer independent trials, or produced less precise estimates once each therapy was isolated from the class. Under GRADE, that lower certainty caps how strongly a panel can recommend, even for a therapy clinicians value.

Written exposure therapy is a useful illustration. It is brief and pragmatic, and interest in it is growing, yet the pooled trial evidence in 2023 was not deep enough to clear the bar for a strong recommendation. A guideline reflects the state of the evidence at publication, and a weaker rank today can strengthen as trials accumulate.

Where medications land

The guideline recommends trauma-focused psychotherapy over medication for people who can engage in it, citing more durable improvement. Among drugs, it recommends sertraline, paroxetine, and venlafaxine, the antidepressants with the most consistent randomized evidence for reducing PTSD symptoms. Fluoxetine, an SSRI like two of those, landed in "neither for nor against" because the direct evidence was judged insufficient, a reminder that GRADE grades specific treatments, not whole drug classes.

At the other end, the panel recommended against benzodiazepines and against cannabis or cannabis-derived products for PTSD, reflecting both weak evidence of benefit and real potential for harm. Those "against" ratings follow the same methodological logic as the endorsements.

What a strong recommendation demands

The through line is that "strong" is earned, not assumed. It generally requires multiple well-conducted randomized trials, a consistent direction of effect, low risk of bias, and estimates precise enough that reviewers are confident the benefit is real and clinically meaningful. A guideline that reserves its strongest language for that standard is being honest about uncertainty rather than implying every listed therapy is interchangeable.

For readers, the practical takeaway is about literacy, not ranking anxiety. A therapy at the top of the list has the sturdiest evidence, and a therapy a tier down may still be a reasonable, evidence-based choice, especially when patient preference or access points toward it. This article is educational and is not medical advice; treatment decisions belong with a qualified clinician who knows the individual.

The 2023 update also works as a case study in how methodology changes conclusions. Nothing about trauma or the human response to it changed between 2017 and 2023. What changed was the rigor of the appraisal, and that alone moved several treatments up or down the page.